Scarica l'app Stockscreener
0.00
100.00%
-2.11
Dopo l'orario di chiusura:
2.15
2.15
+
Precedente Chiudi:
$2.11
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$45.72M
Reddito:
-
Utile/perdita netta:
$-12.94M
Rapporto P/E:
0.00
EPS:
-2.84
Flusso di cassa netto:
$-13.83M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$4.40
Aileron Therapeutics Inc Stock (ALRN) Company Profile
Nome
Aileron Therapeutics Inc
Settore
Industria
Telefono
(737) 802-1989
Indirizzo
12407 N. MOPAC EXPY., AUSTIN, MA
Confronta ALRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALRN
Aileron Therapeutics Inc
|
0.00 | 45.72M | 0 | -12.94M | -13.83M | -2.84 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Aileron Therapeutics Inc Stock (ALRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2017-07-24 | Iniziato | BofA/Merrill | Buy |
| 2017-07-24 | Iniziato | Jefferies | Buy |
| 2017-07-24 | Iniziato | William Blair | Outperform |
Aileron Therapeutics Inc Borsa (ALRN) Ultime notizie
Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf - marketscreener.com
Advancing Oxygen-Based Therapies: Hypoxia Treatment Market - openPR.com
Rein Therapeutics Reports Q1 2025 Financial Results - TipRanks
Rein Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Rein Therapeutics Announces Initiation Of Renew Phase 2 Trial Of Lti-03 In Patients With Ipf - marketscreener.com
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF - marketscreener.com
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - marketscreener.com
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 - marketscreener.com
Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases - marketscreener.com
Hypoxia Treatment Market Growth: From $77.6M in 2022 to $134.3M - openPR.com
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F - PR Newswire
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Longview News-Journal
RNTX stock touches 52-week low at $1.6 amid market challenges - Investing.com
Aileron Therapeutics, Inc. Announces New Appointments - MarketScreener
Peripheral T-cell Lymphoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Companies & Growth Analysis Report by DelveInsight - The Globe and Mail
Reflecting On Productivity Software Stocks’ Q4 Earnings: Dropbox (NASDAQ:DBX) - The Globe and Mail
Artivion (AORT): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
Better Artificial Intelligence Stock: SoundHound AI vs. C3.ai - The Globe and Mail
Did Robinhood Just Say Checkmate to SoFi? - The Globe and Mail
Firing on All Cylinders: Benchmark (NYSE:BHE) Q4 Earnings Lead the Way - The Globe and Mail
Stocks in play: i-80 GOLD CORP. - The Globe and Mail
Lucid (LCID): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
Are XPeng (XPEV) Traders Overpricing Options Ahead of Q4 Earnings? - The Globe and Mail
Will Gasoline Prices Head Higher During the 2025 Driving Season? - The Globe and Mail
Snowflake (SNOW) Q4 Earnings Report Preview: What To Look For - The Globe and Mail
Chemotherapy Induced Anemia Drugs Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, NDA Approvals, Therapies, and Companies by DelveInsight - The Globe and Mail
Chemotherapy Induced Anemia Drugs Market 2032: EMA, PDMA, FDA - openPR
Hypoxia Treatment Market to Witness Substantial Growth by 2031 | - openPR
Theratechnologies (NASDAQ:THTX) vs. Aileron Therapeutics (NASDAQ:ALRN) Head to Head Survey - Defense World
Aileron Therapeutics Reports Q3 2024 Financial Results - MSN
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust - GlobeNewswire
Lockheed Martin Earnings: What To Look For From LMT - The Globe and Mail
Aileron Therapeutics, Inc. announced that it has received $42 million in funding from a group of investors. - Marketscreener.com
Aileron straps in for 2025 with a new name: Rein Therapeutics - Fierce Pharma
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - Marketscreener.com
Aileron Therapeutics, Inc. Announces Board Changes - Marketscreener.com
Aileron Therapeutics, Inc. Announces Board Changes -April 01, 2019 at 06:16 am EDT - Marketscreener.com
Aileron Therapeutics to be Included in the Russell Microcap® Index - Marketscreener.com
Aileron Therapeutics Announces Appointments to Scientific Advisory Board -March 28, 2018 at 07:00 am EDT - Marketscreener.com
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer - Marketscreener.com
Aileron Therapeutics Announces Board Appointments - Marketscreener.com
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - Marketscreener.com
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - Marketscreener.com
Aileron Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Aileron Therapeutics Announces Management Changes - Marketscreener.com
Aileron Therapeutics, Inc. Announces CEO Changes - Marketscreener.com
Aileron Therapeutics Announces Management Changes -September 06, 2018 at 09:10 am EDT - Marketscreener.com
Rein Therapeutics announces name change and new ticker By Investing.com - Investing.com Canada
Rein Therapeutics announces name change and new ticker - Investing.com
Aileron Therapeutics announces rebranding to Rein Therapeutics - MSN
Geode Capital Management LLC Grows Position in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - Defense World
Aileron Therapeutics Inc Azioni (ALRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):